We screened metastatic cancer, carcinoma in situ and their corresponding adjacent tissues by second-generation sequencing and detected the presence of high-frequency mutations in EZH2 in lung cancer primary lesions and brain metastatic tissues. This evidence concerns the gene EZH2 and lung carcinoma.